LumiraDx Demonstrates Use of LumiraDx Platform in Infectious Disease Testing at ECCMID 2022

LumiraDx (London, UK) exhibited at ECCMID live for the first time where it demonstrated the use of its LumiraDx platform in infectious disease testing. The last two editions of ECCMID were only accessible through the website, as the pandemic made impossible to exhibit on live. This year, the 32nd edition of the European Congress of Clinical Microbiology and Infectious Diseases took place in a hybrid event held in person and online.

At ECCMID 2022, LumiraDx demonstrated its transformational point of care solution, the innovative LumiraDx Platform which is designed to perform a broad menu of tests, including infectious disease, cardiovascular disease, diabetes, and coagulation disorders, at point of care and deliver lab-comparable performance with results in less than 12 minutes. The next generation point of care diagnostic system combines a small, portable instrument; microfluidic test strip; simple, standardized workflow; and seamless, secure digital connectivity to the Cloud and hospital IT systems. It is designed to be affordable and accessible for healthcare providers globally, and to strengthen community-based healthcare.

LumiraDx also highlighted its COVID-19 testing solutions for use on the LumiraDx Platform, including its LumiraDx SARS-CoV-2 Ag Test, LumiraDx SARS-CoV-2 Ag Pool Test and LumiraDx SARS-CoV-2 Ab Test.

Related Links:
LumiraDx